EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

Cited by (163)

Items 101–163 of 163

1. Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
   Junru Ye, Yutong Ma, Qiuxiang Ou, Junrong Yan, Bin Ye, Yuping Li · 2022 · Frontiers in Oncology
2. The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
   Yongdong Feng, Guangkuo Zhu, Song Lang, Ping Hao, Guanghui Li, Fanglin Chen, Wenlei Zhuo, Yu‐zhong Duan, Anmei Zhang, Zhengtang Chen et al. · 2021 · Frontiers in Oncology
3. Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance
   Detian Liu, Xiaolin Lü, Wentao Huang, Wei Zhuang · 2023 · Frontiers in Genetics
4. Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure
   Meifang Li, Cheng Lin, Jinghui Lin, Shijie Chen, Lihong Weng, Zhiyong He · 2024 · Oncology Letters
5. Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H
   Huihui Guo, Xilin Zhang, Shangzhi Xie, Tianwei Chen, Dong Xie, Ying Cai, Dawei Cui, Liang Wang, Wei Chen, Xiang Wang · 2022 · International Journal of Oncology
6. The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study
   Shuyang Zhang, Lu Yang, Yaning Yang, Guangjian Yang, Haiyan Xu, Xueliang Niu, Yan Wang · 2023 · Cancer Medicine
7. Antitumor effects of targeting myeloid-derived suppressive cells
   Dong Zeng, Haixia Long, Bo Zhu · 2020 · Translational Cancer Research
8. Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis
   Jun Wang, Feng‐Ting Dao, Lu Yang, Ya‐Zhen Qin · 2020 · Scientific Reports
9. Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
   Jin Tian, Zhiqi Shi, Lili Zhao, Peng Liu, Xiaojun Sun, Lin Long, Jianhua Zang, Jun Xiao · 2024 · The Clinical Respiratory Journal
10. Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non–Small Cell Lung Cancer
    Beung‐Chul Ahn, Charny Park, Moon Soo Kim, Jong Mog Lee, Jin Ho Choi, Hyae Young Kim, Geon Kook Lee, Namhee Yu, Youngjoo Lee, Ji‐Youn Han · 2023 · Cancer Research and Treatment
11. Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review
    Mu-tong CHEN, Baizhi Li, En-Pu Zhang, Qing Liang Zheng · 2023 · Medicine
12. A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma
    Zhiyi Han, Tao Li, Heng Zhang, Kai Liang, Mengfan You, Mengdi Xu, Fan Bai, Tongmei Zhang · 2024 · Molecular Cancer
13. Characterization of monoclonal antibodies generated to the 287–302 amino acid loop of the human epidermal growth factor receptor
    Eric Chun Hei Ho, Antonella Antignani, Robert J. Sarnovsky, David J. FitzGerald · 2019 · Antibody Therapeutics
14. Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors
    Fei Zhou, Caicun Zhou · 2021 · Journal of Thoracic Oncology
15. Immunomodulation on tumor immune microenvironment in acquired targeted therapy resistance and implication for immunotherapy resistance
    Ming-Yu Chou, Muh‐Hwa Yang · 2025 · Translational Oncology
16. Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
    Yusaku Momoi, Shogo Kumagai, Hiroyoshi Nishikawa · 2025 · International Immunology
17. ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC
    Yunhuan Liu, Yong Yu, Congli Hu, Minlin Jiang, Chao Zhao, Xuefei Li, Lei Cheng, Caicun Zhou · 2025 · Cancer Drug Resistance
18. EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation
    Yuanqiang Wu, Li Yh, Lorraine Edna Onzere, Weini Quan, Xueqing Zhang, Jinan Ma · 2025 · Expert Review of Anticancer Therapy
19. Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells
    Bao-Xia Zhao, Yan Zhang, Shen Lu, Mei Li · 2022 · Oncology Reports
20. A Rare Histologic Transformation from EGFR-Positive Lung Adenocarcinoma to EGFR-Negative Squamous Cell Carcinoma After EGFR-TKIs Resistance: A Case Report
    Mengli Qiu, Peiwen Guo, Jieheng Lin, Sisi Wang, Wenping Wang, Jianying Yang, Zhongming Huang, Yang Cao · 2025 · OncoTargets and Therapy
21. EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study
    B Su, Yuwei Xie, Yingnan Zhou, Fumin Shi, Jia Wang, Long Xu · 2025 · Expert Review of Anticancer Therapy
22. Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations
    Élodie Long-Mira, Christophe Bontoux, Guylène Rignol, Véronique Hofman, Sandra Lassalle, Jonathan Benzaquen, Jacques Boutros, Salomé Lalvée, Katia Zahaf, Virginie Lespinet‐Fabre et al. · 2025 · Cancers
23. Fasting-mimicking diet enhances EGFR-TKI efficacy in oral cancer through dual mechanisms: direct cancer cell sensitization and tumor-associated macrophage crosstalk
    Lei Wang, Yujie Wang, Rong Wang, Fu‐Lian Gong, Jiyuan Chen, Yating Yu, Ze-rong Qiu, Yongfang Yuan · 2025 · Frontiers in Pharmacology
24. Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients
    Ming‐Fang Wu, Ya-Hsuan Chang, Hsuan‐Yu Chen, Chao‐Chi Ho, Huei‐Wen Chen · 2023 · Journal of the Formosan Medical Association
25. EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer
    Fei Ye, Xiao Yuan, Wanjun Yu, Yali Ma, Chaoming Mao, Xiaoqin Li, Jian Li, Chunhua Dai, Fen-Hong Qian, Junrong Li et al. · 2024 · Technology in Cancer Research & Treatment
26. Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy
    Liwu Fu, Min Luo · 2025 · Cancer drug discovery and develogment/Cancer drug discovery and development
27. Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study
    Denys Kozakov, Nazarii M. Kobyliak, Sofiia Livshun, Oleksii Seleznov, Olena Koshyk, Alina Matvieieva, Yaroslav V. Shparyk, Oleksii Kolesnik, Yuliia Moskalenko, О. І. Vynnychenko et al. · 2025 · Frontiers in Medicine
28. Effect of neoadjuvant targeted therapy on the tumor microenvironment in resectable lung adenocarcinoma
    Ling Yi, Heng Yao, Zhexin Bai, Ziwei Xu, Huimin Li, Yu-Ting Cheng, Chong Wang · 2025 · Cellular Oncology
29. Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention strategies
    Xiaoli An, Jie Xie, Weiyun Wang, Ting Long, Qinhao Liang, Jing Hou · 2026 · Critical Reviews in Oncology/Hematology
30. Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor–Refractory NSCLC
    Haoyue Guo, Yuanyuan Wang, Meng Diao, Ruoshuang Han, Taiping He, Yuhan Wu, Qianyi Wang, Lei Cheng, Chao Zhao, Xuefei Li et al. · 2026 · Journal of Thoracic Oncology
31. PD ‐ L1 Expression and Histopathological Features in EGFR ‐Mutated Non‐Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR ‐Tyrosine Kinase Inhibitors Resistance
    Toshiyuki Sumi, Taiki Ishigooka, Keigo Matsuura, Takumi Ikeda, Yuichi Yamada, Kotomi Arioka, Hirofumi Chiba · 2026 · Thoracic Cancer
32. Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges
    Shuyi Hu, Xinhong Shi, Qin Hu, Xiaohua Wang, Guoren Zhou · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
33. Immunotherapy for patients with EGFR-TKI-resistant non-small-cell lung cancer: Potential mechanisms, efficacy predictors, and therapeutic integration
    Xinwei Wu, Yangbin Shi, Danni Wang, Beibei Liu, Yanwei Zhang, Lele Zhang, Fangfei Qian, Wei Zhang · 2026 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
34. [Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
    Yaoyao Liu, Jianlong Miao · 2024 · PubMed Central
35. Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study
    Kan Jiang, Lin Wu, Xinlong Zheng, Yiquan Xu, Qian Miao, Xiaobin Zheng, Longfeng Zhang, Cheng Huang, Gen Lin · 2024 · BMC Pulmonary Medicine
36. Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
    Shubin Chen, Qitao Yu, Wei Jiang, Yukun Lu, Yun Fu Zhao, Huilin Wang · 2023 · Frontiers in Medicine
37. Immunohistochemical analysis of glassy cell carcinoma of the cervix reveals robust lymphocyte infiltrate and the expression of targetable inhibitory immune checkpoints
    Erin A. Blake, Malcolm Strachan Ross, Megan E. Ross, Koji Matsuo, Emily Silverstein, Lilibeth Ramilo Torno, Rohit Bhargava, Miriam D. Post, Diane M. Da Silva, Sarah Elizabeth Taylor et al. · 2021 · Archives of Gynecology and Obstetrics
38. Biological Electric Fields Guide Directional Migration and Promote Epithelial–Mesenchymal Transition in Lung Cancer
    Conghua Lu, Ying Zhang, Xiaolin Tang, Chen Hu, Xiaoli Jin, Bing Song, Sanjun Zhao, Yong He, Li Li · 2023 · Bioelectricity
39. HMOX1 expression influence the role of macrophage in EGFR-TKI resistance of lung adenocarcinoma
    Hongkun Fang, Hao Wang, Xinyue Liu, Yi Shin Deng, Lishu Zhao, Kandi Xu, Ye Li, Yujin Liu, Wencheng Zhao, Ying Zhou et al. · 2025 · International Immunopharmacology
40. Insulin‐Loaded Muco‐Inert Nanoparticles Based on L ‐valine‐modified Chitosan and Fucoidan for Enhanced Oral Delivery
    Changsheng Gan, Huiya Li, Lei Yang, Tianling Zhang, Kun Xu, Honglei Wang, shiji Sun, Chuanxun Yuan, Ailing Hui, Wencheng Zhang · 2026 · Macromolecular Bioscience
41. Tumor-immune crosstalk in lung cancer: emerging roles of long non-coding RNAs
    Upasna Madan, Riitta Lahesmaa, Anil K. Thotakura · 2026 · Frontiers in Immunology
42. [Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].
    Ran Chen, Chang Jiang, Li Ma, Shucai Zhang · 2022 · PubMed Central
43. Construction of a cuproptosis-tricarboxylic acid cycle-associated lncRNA model to predict the prognosis of non-small cell lung cancer
    Xiangdong D. Li, Yunlong Zhao, Shengjie Wei, Yuqing Dai, Chun Yi · 2024 · Translational Cancer Research
44. Interleukin 35 Activates Intratumor Neovascularization Via Enhanced Secretion of FGF2 in Hepatocellular Carcinoma Through The Recruitment of Neutrophils, and Blocking it Could Facilitate The Efficacy of The PD-1 Antibody
    Wei Gan, Meixia Zhang, Jinlong Huang, Pei‐Yun Zhou, Chengji J. Zhou, Gao Liu, Yi‐Peng Fu, Bao‐Ye Sun, Chuyu Jing, Ruo‐Yu Guan et al. · 2020 · Research Square
45. Establishment of Prediction Models for Lung Cancer NOG/PDX Models: A Guideline for Machine Learning in Small Biomedical Datasets
    Haoyue Guo, Li Diao, Hui Qi, Chunlei Dai, Yu Chen, Xuzhen Tang, Yayi He · 2020 · Research Square
46. Sijunzi Tang and gefitinib cooperate to inhibit Lung cancer progression by modulating the pre-metastatic niche
    Mingyu Zhang, Wei Chen, Ruisheng Li, Xingjie Li, Chunyu Li, Guohui Li · 2021 · Research Square
47. Modulation of Myeloid-Derived Suppressor Cells Amplification by Tumor Microenvironment
    瑞新 张 · 2021 · Advances in Clinical Medicine
48. Establishment of prediction models for lung cancer NOG/PDX models: A guideline for machine learning in small biomedical datasets
    Haoyue Guo, Li Diao, Hui Qi, Chunlei Dai, Yu Chen, Xuzhen Tang, Yayi He · 2020 · Research Square
49. O estudo das células mieloderivadas supressoras na tumorigênese pulmonar em camundongos selecionados para máxima ou mínima resposta inflamatória aguda
    Tamíris Isabela Guidugli · 2019
50. [Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].
    Yujun Zheng, Wei Jiang, Jing Li, Lulu Dai, Dongyan Chen, Yanjun Li, Lei Huang, Mingji Wang · 2022 · PubMed Central
51. Data from Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD
    Hsin-Fang Tu, Chun‐Jung Ko, Ching‐Tai Lee, Cheng‐Fan Lee, Shao-Wei Lan, Hsin-Hsien Lin, Hsin-Ying Lin, Chia‐Chi Ku, Der‐Yen Lee, I‐Chun Chen et al. · 2023
52. สหสมพนธของลกษณะสภาวะแวดลอมรอบเซลลมะเรงในผปวยโรคมะเรงปอดชนดไมใชเซลลเลกระยะลกลามทมยนกลายพนธอจเอฟอารและไดรบยามงเปาอจเอฟอาร
    ชัยพงศ์ งามโชควัฒนา, ชนิดา วินะยานุวัติคุณ, ปุญชวิษฐ์ จันทรานุวัฒน์ · 2022
53. Research Progress of EGFR-TKIs Resistance and PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer
    雅婷 温 · 2024 · Advances in Clinical Medicine
54. Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial
    Enya E. Scanlon, A. Lavery, Mohammad Albraikat, Leanne S. Stevenson, C. Kennedy, Ryan M. Byrne, A. Walker, B Mullan-Young, Damian T McManus, Pradeep Singh Virdee et al. · 2024 · ESMO Open
55. Rebuilding TME may open new doors for improving the prognosis of EGFR mutation patients
    Rui Han, Conghua Lu, Yong He · 2024 · Cancer Letters
56. Pathological complete response and long-term survival by pembrolizumab based immunochemotherapy in epidermal growth factor receptor mutated non-small cell lung cancer post-tyrosine kinase inhibitor failure: a case report and tumor microenvironment analysis
    Sangtian Liu, Wenhua Liang, Shicui Quan, Qilin Deng, Wenhai Fu, Yalei Zhang, Hong Du, Jianxing He · 2025 · Translational Lung Cancer Research
57. Integrative prognostic model incorporating high mobility group box 1 subcellular localization and tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma
    Yao Liu, Miyako Shimasaki, Motona Kumagai, Jia Han, Akihiro Shioya, Masaru Sakurai, Hidetaka Uramoto, Sohsuke Yamada · 2025 · Diagnostic Pathology
58. Interleukin 35 promotes progression of hepatocellular carcinoma by recruiting neutrophils
    Wei Gan, Guo-Qiang Sun, Jinlong Huang, Bao‐Ye Sun, Zhu-Tao Wang, Yang Zhang-fu, Cheng Zhou, Yong Yi, Shuang-Jian Qiu · 2026 · Translational Oncology
59. The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung cancer
    X L He, Tiantian Tian, Yanjing Ma, Qianwei Cai, Guodong Deng, Xiaotian Zhang, Ning Liang · 2026 · Journal of Cancer Research and Therapeutics
60. Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
    Aaron C. Tan, Jia Chi. Yeo, Jacob J.S. Alvarez, Mengyuan Pang, Yu Amanda Guo, Regina Hoo, Angela Maria Takano, Boon‐Hean Ong, Denise L M Goh, Joe Poh-Sheng Yeong et al. · 2026 · Cancer Research Communications
61. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced cutaneous squamous cell carcinoma
    Jeremy Mo, Ann‐Sophie Bohne, Mirjam Nägeli, Caroline Gaudy‐Marqueste, Charley Chen, Anne Zaremba, John Park, Rahul Ladwa, Nicholas Della Marta, Margarida Matias et al. · 2026 · EJC Skin Cancer
62. Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology
    William W.-G. Jia, Ronghua Zhao, Howard L. Kaufman, Robert L. Martuza · 2026 · Nature Reviews Clinical Oncology
63. Integrative bioinformatics screening of a M2 macrophage-associated gene signature for osimertinib resistance
    Yajie Huang, Yi Zhang, Jian Shi · 2026 · Frontiers in Genetics